Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040)

BACKGROUND: Cancer chemotherapy indications for patients with poor performance status and advanced lung cancer are limited. Molecular targeted drugs, including epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors, can be used in patients with poor performance status owing to their high...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukui, Tomoya, Sasaki, Jiichiro, Igawa, Satoshi, Kada, Akiko, Saito, Toshiki I., Kogure, Yoshihito, Okamoto, Hiroaki, Naoki, Katsuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753257/
https://www.ncbi.nlm.nih.gov/pubmed/36522630
http://dx.doi.org/10.1186/s12885-022-10409-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753257/
https://www.ncbi.nlm.nih.gov/pubmed/36522630
http://dx.doi.org/10.1186/s12885-022-10409-6

Ejemplares similares